nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Capturing the true burden of Shigella and ETEC: The way forward
|
Khalil, Ibrahim |
|
2019 |
37 |
34 |
p. 4784-4786 |
artikel |
2 |
Clinical endpoints for efficacy studies
|
Porter, Chad K. |
|
2019 |
37 |
34 |
p. 4814-4822 |
artikel |
3 |
Editorial Board/Aims and Scope
|
|
|
2019 |
37 |
34 |
p. IFC |
artikel |
4 |
How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
|
Giersing, Birgitte K. |
|
2019 |
37 |
34 |
p. 4778-4783 |
artikel |
5 |
How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions
|
Mottram, Lynda |
|
2019 |
37 |
34 |
p. 4805-4810 |
artikel |
6 |
Implications and measurement of herd protection (indirect effects) for enteric vaccine development
|
Wierzba, Thomas F. |
|
2019 |
37 |
34 |
p. 4775-4777 |
artikel |
7 |
Preface
|
Walker, Richard I. |
|
2019 |
37 |
34 |
p. 4767 |
artikel |
8 |
Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development
|
Mani, Sachin |
|
2019 |
37 |
34 |
p. 4787-4793 |
artikel |
9 |
Technical product attributes in development of an oral enteric vaccine for infants
|
White, Jessica A. |
|
2019 |
37 |
34 |
p. 4800-4804 |
artikel |
10 |
The way forward for ETEC controlled human infection models (CHIMs)
|
Hanevik, Kurt |
|
2019 |
37 |
34 |
p. 4794-4799 |
artikel |
11 |
Using advocacy to increase investment in enteric vaccine development
|
Randall, Hope |
|
2019 |
37 |
34 |
p. 4811-4813 |
artikel |
12 |
Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference
|
Barry, Eileen |
|
2019 |
37 |
34 |
p. 4768-4774 |
artikel |